Cargando…
Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence
A proportion of patients with interstitial lung diseases (ILDs) are at risk of developing a progressive-fibrosing phenotype, which is associated with a deterioration in lung function and early mortality. In addition to idiopathic pulmonary fibrosis (IPF), fibrosing ILDs that may present a progressiv...
Autores principales: | Richeldi, Luca, Varone, Francesco, Bergna, Miguel, de Andrade, Joao, Falk, Jeremy, Hallowell, Robert, Jouneau, Stéphane, Kondoh, Yasuhiro, Morrow, Lee, Randerath, Winfried, Strek, Mary, Tabaj, Gabriela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488647/ https://www.ncbi.nlm.nih.gov/pubmed/30578333 http://dx.doi.org/10.1183/16000617.0074-2018 |
Ejemplares similares
-
Management of patients with fibrosing interstitial lung diseases
por: Morrow, Lee E, et al.
Publicado: (2021) -
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
por: Cottin, Vincent, et al.
Publicado: (2021) -
Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases
por: Brown, Kevin K., et al.
Publicado: (2022) -
Progression of fibrosing interstitial lung disease
por: Wong, Alyson W., et al.
Publicado: (2020) -
Management of Fibrosing Interstitial Lung Diseases
por: Maher, Toby M., et al.
Publicado: (2019)